Max Robotics — Global Service Robot Directory + US Certification

About

S. Fracalanza is a urological surgeon and researcher whose work has significantly advanced the understanding and adoption of minimally invasive techniques for prostate cancer treatment, particularly robot-assisted laparoscopic radical prostatectomy (RALP). Working within a European institutional context, Fracalanza was among the early adopters and rigorous evaluators of the da Vinci robotic surgical system, helping to establish its clinical credibility through carefully designed prospective comparative studies. Fracalanza's most influential contribution, a 2009 prospective non-randomized trial comparing RALP with traditional retropubic radical prostatectomy (RRP), has accumulated 218 citations, reflecting its importance in guiding surgical decision-making across urology departments worldwide. Earlier work from 2008 documented the learning curve associated with robotic prostatectomy and assessed its invasiveness relative to open surgery through biochemical markers of tissue damage, garnering a combined 169 citations. Together, these studies provided some of the earliest objective European evidence that RALP could achieve comparable or superior functional outcomes with reduced surgical trauma. Fracalanza's research has been instrumental for trainees and established surgeons alike seeking evidence-based benchmarks for integrating robotic surgery into urological practice.